Skip to main content

AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer

AstraZeneca and Merck/MSD were approved to sell their jointly marketed PARP inhibitor in China as a first-line maintenance treatment for BRCA-mutated ovarian cancer. In a Phase III trial among patients who responded to platinum-based chemotherapy, 60% of Lynparza patients hit the 36-month point without disease progression or death, against 27% for women receiving placebo, a 70% improvement. Results of the Phase III SOLO-1 trial showed 15% of ovarian cancer patients have a germline (inherited) BRCA 1/2 mutation and 7% have a somatic (acquired) mutation. More details.... Stock Symbols: (NYSE: AZN) (NYSE: MRK) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.